Univariable and Cox proportional hazards regression analysis of variables associated with survival
| Features | Univariable analysis | Cox proportional hazards regression survival analysis | |||
| Non-Survivors, n=72 | Survivors, n=190 | P value | HR (95% CI) | P value | |
| Colchicine treatment (%) | 20/72 (28) | 102/190 (54) | 0.0002 | 0.151 (0.062 to 0.368) | <0.0001 |
| Male (%) | 49 (68) | 118 (62) | 0.37 | 1.220 (0.586 to 2.543) | 0.59 |
| Age (years), mean (SD) | 78.4 (7.5) | 66.6 (13.4) | <0.0001 | 1.049 (1.007 to 1.093) | 0.021 |
| Cardiovascular comorbidities* (%) | 46/52 (88) | 120/166 (72) | 0.017 | 0.637 (0.211 to 1.920) | 0.42 |
| Chronic obstructive bronchopneumonia (%) | 11/50 (22) | 30/164 (18) | 0.56 | 1.164 (0.519 to 2.611) | 0.71 |
| Neoplastic comorbidities (%) | 15/52 (29) | 18/168 (11) | 0.0014 | 0.549 (0.261 to 1.157) | 0.11 |
| Hydroxychloroquine treatment (%) | 34/66 (52) | 90/174 (52) | 0.98 | 1.359 (0.530 to 3.486) | 0.52 |
| Lopinavir/ritonavir treatment (%) | 19/67 (28) | 44/178 (25) | 0.56 | 1.037 (0.350 to 3.074) | 0.94 |
| Dexamethasone treatment (%) | 39/67 (58) | 68/179 (38) | 0.0044 | 0.870 (0.414 to 1.828) | 0.71 |
| PaO2/FiO2 (mm Hg/%), mean (SD) | 155.8 (76.7) | 229.8 (100.8) | 0.50 | 0.994 (0.990 to 0.998) | 0.0048 |
| Ferritin (ng/mL), mean (SD) | 1839 (1561) | 1450 (1679) | 0.50 | 1.002 (1.001 to 1.004) | 0.010 |
| C reactive protein (mg/L), mean (SD) | 178.3 (86.7) | 121.5 (87.8) | 0.16 | 1.002 (0.998 to 1.006) | 0.27 |
*Cardiovascular comorbidities: any history of cardiovascular disease, including coronary heart disease (ie, myocardial infarction, angina, coronary revascularisation), cerebrovascular disease (ie, stroke, transient ischaemic attack) and/or peripheral arterial disease, diabetes mellitus, arterial hypertension.